key: cord-0742198-qlvw7yvr
authors: Sivanandan, Sindhu; Chawla, Deepak; Kumar, Praveen
title: Update to Perinatal-Neonatal Management of COVID-19 Guidelines
date: 2021-11-22
journal: Indian Pediatr
DOI: 10.1007/s13312-022-2423-7
sha: 821b2bb25649aaa6c3dc00eebceddbdd7f93cd70
doc_id: 742198
cord_uid: qlvw7yvr

The guidelines for diagnosing and managing perinatal SARS-CoV-2 infection for the Indian context were last updated in May 2020. Newer evidence, the evolution of the pandemic, and its significant impact on mother-infant dyads led us to review and revise the guideline. This article summarizes the salient changes in the perinatal-neonatal management of COVID-19.

I ndia witnessed the second surge of COVID-19 in March 2021 due to the SARS-CoV-2 double-mutant strain B.1.617 [1] . During this period, the test positivity rate was more than 20%, and pregnant women were noted to experience severe illness [2] .The initial guidelines on diagnosis and management of perinatal SARS-CoV-2 infection in India were published in April 2020 [3] and updated in May 2020. The guideline development group (GDG) updated the systematic review to evaluate new evidence and used the GRADE methodology to develop recommendations [4] . We, herein, summarize the updates on managing pregnant women and neonates exposed to COVID-19. Readers may refer to the version 3 of the complete recommendations for more details [4] .

COVID-19 in pregnancy is associated with an increased risk of severe disease and pregnancy-related compli-cations such as preeclampsia/eclampsia, gestational diabetes, and thrombosis [5, 6] . Pregnant women with COVID-19 have a two-fold higher risk of needing intensive care, mechanical ventilation, extracorporeal membrane oxygenation, and higher mortality [7] . Increased maternal age, obesity, preexisting comorbidity, chronic hyper-tension, diabetes, and preeclampsia are associated with severe illness [7] . The risk of stillbirth, intrauterine growth restriction, and preterm birth is increased twofold. The updated recommendations are listed below:

i) The updated COVID-19 testing strategy for pregnant women (Table I) is based on the Indian Council of Medical Research (ICMR) recommendations [2] .

ii) The decision to manage a COVID-19 positive pregnant woman at home or in a health facility depends on obstetric risk factors, comorbidities, the severity of COVID-19 illness, and social conditions. Women with obstetric complications, moderate or severe COVID-19 illness, unsuitable social conditions, and situations where telemonitoring is difficult should be admitted to a health facility. Home quarantine is cost-effective, but tele-consultation services are mandatory for monitoring.

iii) Maternity care services and other specialty services are available at Dedicated COVID Health Centers (DCHC) and Dedicated COVID Hospitals (DCH). All suspected or confirmed COVID-19 pregnant women should deliver at DCHC or DCH as per disease severity and availability of obstetric and neonatal services.

iv) The use of steroids in pregnant women with COVID-19 depends on fetal and maternal indications (Table II) . Dexamethasone given for ten days or until discharge to hospitalized patients with moderate to severe COVID-19 on oxygen or respiratory support has been shown to reduce mortality by 30% [8] . For fetal lung maturity, dexamethasone is given 6 mg IM every 12 hours for four doses. When used solely for maternal indications, alternate steroids (methylprednisolone, prednisolone, or hydrocortisone) can be considered based on availability, cost, and individual preference [9, 10] . 

Yes Resource limited Dexamethasone 6 mg IM every 12 hourly for four doses (2 days) followed by 6 mg/day PO/IV for eight more days or until discharge, whichever is earlier.

Resourceful (available, Dexamethasone 6 mg IM every 12 hours for four doses affordable, and maternal (2 days) followed by Methylprednisolone or Prednisolone preference for dexamethasone or Hydrocortisone in equivalent doses for eight more days alternatives) or until discharge, whichever is earlier.

pregnancy or perform a caesarean section. However, a caesarean section may be indicated to manage respiratory failure in critically ill pregnant women with refractory hypoxemia.

vi) Symptomatic pregnant women with fever >39°C despite the use of antipyretics, moderate or severe COVID-19 illness, or comorbid conditions (poorly controlled hypertension or diabetes, preeclampsia, pre-labor rupture of membranes, bleeding per vaginum) should be admitted to a DCH having an intensive care unit with multidisciplinary support. Management of COVID-19 illness in pregnancy is provided in Box I.

vii) COVID-19 vaccines can be offered at any gestational age in pregnancy, but the second dose should preferably be completed before the third trimester. Physicians should inform pregnant and lactating women of the risks of COVID-19, the benefits of vaccination in the local epidemiological context, and limited safety data and assist them in the informed decision-making process.

Among neonates born to COVID-19 positive mothers, the proportion with a positive test ranges from 0.5% to 13% (median 2%) [5, 6] . The NNF COVID-19 registry observed a 10% positivity rate [11] . This variability is explained by the variation in testing policy and the population profile. transmission can be reduced if mothers wear a triple layer mask and strictly adhere to respiratory etiquettes. The use of filters with T-piece/bag-mask devices and aerosol boxes forintubation is not recommended.

ii) Mother-infant dyads should room-in, and exclusive breastfeeding should be encouraged regardless of maternal COVID-19 status. When direct feeding or rooming-in is not feasible, the mother's expressed milk should be provided.

iii) Kangaroo care is recommended for low birthweight neonates regardless of the COVID-19 status of the mother or neonate.

iv) Symptomatic neonates with suspected COVID-19 should be isolated in a COVID designated area. The suspect and confirmed COVID-19 cases should be segregated.

v) All forms of respiratory support are at risk of generating aerosols, and healthcare providers must wear appropriate PPE. The area providing respiratory support should preferably be a negative air pressure area.

vi) The updated testing strategy for various scenarios is provided in Table III viii) Stable mother-infant dyads may be discharged from the health facility after 24-48 hours of delivery if discharge criteria are met, and birth vaccination is completed. All COVID exposed neonates should be followed up for at least 14 days and preferably till 28 days of life.

ix) The GDG recommends using the WHO case definition for MIS in children for the neonatal age. A 2-tiered approach -proposed by the American College of

Home isolation with active surveillance by telemonitoring or admission to a health facility based on obstetric risk factors, comorbidities, and social conditions Indications for hospitalization: Worsening dyspnea, unremitting fever >39°C despite antipyretics, inability to tolerate oral hydration and medications, persistent pleuritic chest pain, confusion, or obstetric complications.

Home care comprises supportive measures, e.g., hydration, adequate rest, and frequent ambulation with increased activity as tolerated.

The use of ivermectin or doxycycline is contraindicated.

Vitamin C, Vitamin D, and Zinc are not recommended for the treatment of COVID-19.

Admit to a dedicated COVID hospital with a high dependency unit or intensive care unit

Oxygen therapy: Maintain SpO2>94%. Awake-prone positioning if feasible and acceptable.

Remdesivir: Remdesivir should not be withheld from pregnant patients if indicated (patients requiring oxygen therapy, especially early in the disease course). Guidelines issued by the government about rationale use of remdesivir should be followed Venous thromboembolism prophylaxis: All pregnant women with COVID-19 should be assessed for the risk of venous thromboprophylaxis and prescribed prophylactic anticoagulation with low molecular weight heparin/ unfractionated heparin (e.g., enoxaparin 40 mg once daily or dalteparin 5000 IU once daily) and continued for ten days following hospital discharge unless there is a contraindication.

Tocilizumab: The use of tocilizumab (interleukin-6 receptor antagonist) should be considered for women meeting the criteria, i.e., hypoxia and systemic inflammation. During pregnancy, decisions about tocilizumab administration must include shared decision-making between the pregnant woman, family, and the healthcare provider.

Monoclonal antibody: Monoclonal antibody therapy such as bamlanivimab-etesevimab and the casirivimab-imdevimab combination should not be withheld from pregnant patients if they qualify for its use (non-hospitalized patients with mild to moderate COVID-19 who are at high risk for progressing to severe disease and hospitalization) after a discussion of the potential benefits and risks.

There is no role for convalescent plasma therapy PERINATAL-NEONATAL MANAGEMENT OF COVID-19 Rheumatology is recommended for evaluation of a suspect case. Treatment options include intravenous immunoglobulin, methylprednisolone, and aspirin (Web Fig 1) . Neonates with suspected MIS should be managed at tertiary care hospitals where multidisciplinary and cardiology support is available.

The updated perinatal COVID guideline addresses the use of antenatal steroids, COVID vaccination for pregnant and lactating women, testing and treatment of COVID-19, and the multisystem inflammatory syndrome in neonates.

SARS-CoV-2 spike mutations, L452R, T478K, E484Q and P681R, in the second wave of COVID-19 in Maharashtra

Perinatal-Neonatal Management of COVID-19 Infection -Guidelines of the Federation of Obstetric and Gynaecological Societies of India (FOGSI), National Neonatology Forum of India (NNF), and Indian Academy of Pediatrics (IAP)

Advisory for COVID-19 testing during the second wave of the pandemic

Perinatal-Neonatal Management of COVID-19-Clinical practice guidelines (Version 3.0). Accessed

Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: The INTERCOVID Multinational Cohort Study

Pregnancy and neonatal outcomes of COVID-19: coreporting of common outcomes from PAN-COVID and AAP-SONPM registries

for PregCOV-19 living systematic review consortium. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and metaanalysis

Dexamethasone in hospitalized patients with COVID-19

Corticosteroids use in pregnant women with COVID-19: Recommendations from available evidence

World Health Organization. Corticosteroids for COVID-19

National Neonatology Forum (NNF) COVID-19 Registry Group. Outcomes of neonates born to mothers with coronavirus disease 2019 (COVID-19) -National Neonatology Forum (NNF) India COVID-19 Registry